Loading...
KLOW
Add to Wishlist
Anti-Inflammatory Research Blend for Gut and Recovery Studies
In Stock
3ml
$180.00$216.00
You Save
$36.00In Stock — Ships Same Day
Includes
3ml research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
The KLOW blend is a gut-health and anti-inflammatory research formulation combining KPV (Lys-Pro-Val), BPC-157 (Body Protection Compound-157), and Larazotide in a single vial to target gastrointestinal repair and systemic inflammation through three complementary mechanisms. KPV, a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), has been extensively studied for its potent anti-inflammatory activity mediated through direct inhibition of the NF-kB pathway, the master transcription factor controlling expression of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. BPC-157, a pentadecapeptide derived from gastric juice proteins, has been researched for accelerating gastrointestinal mucosal repair, restoring intestinal tight junction integrity, and modulating the gut-brain axis through nitric oxide system regulation. Larazotide acetate is a synthetic peptide investigated for its ability to regulate zonulin-mediated tight junction opening, specifically targeting the paracellular permeability pathway that is central to intestinal barrier dysfunction research. The rationale for combining these three compounds addresses inflammation at its source (KPV), promotes active tissue repair of damaged mucosa (BPC-157), and reinforces the structural integrity of the intestinal barrier (Larazotide), providing a multi-mechanism approach to gastrointestinal and inflammatory research.
Handling & Storage
Published research protocols reference subcutaneous or oral administration routes. Store refrigerated at 2-8°C. Consult applicable literature for specific research applications.
Published Research Protocols
Published research protocols reference daily administration in 4-8 week cycles. Consult applicable literature for specific research applications.
Research Applications
Gut Barrier Repair
BPC-157 has been researched for accelerating the repair of gastrointestinal mucosal damage by promoting angiogenesis at injury sites, upregulating growth factor expression (VEGF, EGF), and restoring tight junction protein assembly including occludin and ZO-1. Larazotide complements this by specifically targeting zonulin-mediated tight junction regulation, addressing the paracellular permeability pathway that underlies intestinal barrier dysfunction in research models.
Initial effects within first month
NF-kB Suppression
KPV has been studied for directly entering cells and inhibiting NF-kB nuclear translocation, effectively suppressing the transcription of key pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. Unlike broader anti-inflammatory agents, KPV targets this specific master regulatory pathway, which has been shown in research to be constitutively activated in chronic intestinal inflammation models, making it particularly relevant for gut-focused inflammatory research.
Initial effects within first month
Systemic Inflammation
The combined action of KPV-mediated NF-kB suppression, BPC-157-mediated tissue repair, and Larazotide-mediated barrier restoration has been researched for reducing circulating levels of inflammatory markers and pro-inflammatory cytokines. By addressing the gut as a primary source of systemic inflammation through barrier repair and local anti-inflammatory action, this blend targets the gut-systemic inflammation axis that is central to current immunology research.
Initial effects within first month
Frequently Asked Questions
What peptides are in the KLOW blend?
The KLOW blend contains KPV (Lys-Pro-Val, a tripeptide derived from alpha-MSH studied for NF-kB pathway inhibition), BPC-157 (a 15-amino-acid gastric peptide researched for gastrointestinal mucosal repair and tight junction restoration), and Larazotide acetate (a synthetic peptide investigated for regulating zonulin-mediated intestinal permeability). Each component is individually verified at 99%+ purity before being combined under sterile cGMP conditions.
How do KPV, BPC-157, and Larazotide complement each other?
Each peptide addresses a different aspect of gut health and inflammation. KPV directly suppresses the NF-kB inflammatory cascade that drives chronic intestinal inflammation. BPC-157 promotes active repair of damaged mucosal tissue through growth factor modulation and angiogenesis. Larazotide specifically targets zonulin-mediated tight junction dysregulation that underlies increased intestinal permeability. Together, they address inflammation suppression, tissue repair, and barrier integrity — three distinct pillars of gastrointestinal health research.
How should the KLOW blend be stored?
Store lyophilized powder at -20°C for long-term storage or at 2-8°C for near-term use. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 30 days. KPV is a small tripeptide that is relatively stable, but BPC-157 can be sensitive to extreme pH values, so avoid reconstituting with acidic or basic solutions. Standard bacteriostatic water at neutral pH is optimal for maintaining all three components.
Can the KLOW blend be administered orally for gut research?
Published research protocols for both KPV and BPC-157 reference oral administration routes, as both peptides have been studied for stability in the gastrointestinal environment and local activity on intestinal tissue. Larazotide was originally investigated as an oral compound targeting intestinal tight junctions. The blend is supplied as a lyophilized powder for reconstitution, and the administration route depends on the specific research protocol. Consult applicable literature for oral versus subcutaneous research methodologies.
Is this product for human use?
No. This product is sold exclusively for in-vitro research, laboratory investigation, and educational purposes. It is not intended or approved for human consumption, clinical treatment of gastrointestinal conditions, or self-administration. All researchers must comply with applicable institutional guidelines and jurisdictional regulations.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
